News By Tag
News By Place
Follow on Google News
Global Idiopathic Pulmonary Fibrosis (IPF) Market: Insights, Pipeline and Forecast (2021-2026)
The Global Idiopathic Pulmonary Fibrosis Market has been analysed By Country (United States, Canada, Germany, France, United Kingdom, Spain, Italy, China, Japan, India).
By: Azoth Analytics
The primary driver of growth in the IPF market in recent years has been an increased use of the high-priced Pirfenidone (Esbriet) and Nintedanib (Ofev) brands in favour of off-label pharmacological therapies and non-pharmacological treatments. Prior to the approval of these drugs, cheap corticosteroids and immunosuppressant's were used to treat IPF despite negative recommendations in evidence-based guidelines for general treatment.
The major factors that drive the growth of the global idiopathic pulmonary fibrosis market include a rise in the prevalence of fibrotic disease and an increase in the geriatric population. In addition, a surge in demand for cost-effective drugs and the introduction of advanced treatment options propel market growth. Furthermore, changing lifestyle patterns and increasing consumption of nicotine products is providing a thrust to the market growth.
Scope of the Report
For more Information:
(Business Development Manager)
Address: CS - 55, Third Floor, Ansal Plaza,
Tel: +91-120- 4298235
Mail ID - firstname.lastname@example.org